(Q33895450)

29 July 2017

title

Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression (English)

1 reference

29 July 2017

0 references

Schatzberg AF

1

1 reference

29 July 2017

Kraemer HC

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

29 July 2017

published in

Biological Psychiatry

1 reference

29 July 2017

volume

47

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

736-744

1 reference

Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Placebo as a treatment for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Placebo response in depression: a search for predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Clinical features of depressed patients who do and do not improve with placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

The earth is round (p < .05).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Sertraline in the prevention of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Which depressions respond to placebo?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Three-year outcomes for maintenance therapies in recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Delusional depression. A distinct clinical entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Clinical significance: A statistical approach to defining meaningful change in psychotherapy research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Measuring the potency of risk factors for clinical or policy significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Cumulative meta-analysis of therapeutic trials for myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Use of pattern analysis to identify true drug response. A replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Identification of true drug response to antidepressants. Use of pattern analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

A strategy to use soft data effectively in randomized controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Investigating onset, cessation, relapse, and recovery: why you should, and how you can, use discrete-time survival analysis to examine event occurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900846-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(00)00846-5

1 reference

29 July 2017

1 reference